Improves lipoprotein profile more in women; CVD event reduction similar for men, women
For patients with type 2 diabetes, fenofibrate is effective in women, improving their lipoprotein profile more than in men, according to a study published in Diabetologia. Michael C. d’Emden, Ph.D., from the Royal Brisbane Hospital in Australia, and colleagues examined sex-related differences in the impact of fenofibrate on major cardiovascular events in type 2 diabetes. Data were included from 3,657 women and 6,138 men with type 2 diabetes, not using statins, who were allocated to fenofibrate or placebo for a five-year period. The researchers found that, in both sexes, baseline total cholesterol, low-density lipoproteincholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), non-HDL-C, apolipoproteins AI and B, and triacylglycerol levels improved with fenofibrate (all P < 0.001). In women,fenofibrate induced greater reductions in total cholesterol, LDL-C, non-HDL-C, and apolipoprotein B (all P < 0.001), irrespective of menopausal status and statin intake. Fenofibrate reduced total cardiovascular outcomes by 30 and 13 percent, respectively, in women and men (P = 0.008 and 0.07, respectively), after adjustment for confounders, with no indication of a treatment-by-sex interaction (P > 0.1). Among patients with high triacylglycerol levels and low HDL-C, there were cardiac outcome reductions of 30 and 24 percent in women and men, respectively, with fenofibrate, with no indication of treatment-by-sex interaction (P > 0.1).
Source : HealthDay News, August,2014